Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
rachel.roberts@ndm.ox.ac.uk

Research groups

Malaria Programme: Pre-erythrocytic Vaccines

Rachel Roberts

Project Manager, Multi-Stage Malaria Vaccine Consortium (MMVC)

Recent publications

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article

Datoo MS. et al, (2022), The Lancet. Infectious diseases
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Journal article

Datoo MS. et al, (2021), The Lancet, 397, 1809 - 1818
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Journal article

Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Journal article

Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Journal article

Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40

More publications